BR112012022873A2 - formulações orais e sais lipofílicos de metilnaltrexona - Google Patents

formulações orais e sais lipofílicos de metilnaltrexona

Info

Publication number
BR112012022873A2
BR112012022873A2 BR112012022873A BR112012022873A BR112012022873A2 BR 112012022873 A2 BR112012022873 A2 BR 112012022873A2 BR 112012022873 A BR112012022873 A BR 112012022873A BR 112012022873 A BR112012022873 A BR 112012022873A BR 112012022873 A2 BR112012022873 A2 BR 112012022873A2
Authority
BR
Brazil
Prior art keywords
methylnaltrexone
oral formulations
lipophilic salts
lipophilic
salts
Prior art date
Application number
BR112012022873A
Other languages
English (en)
Other versions
BR112012022873B1 (pt
Inventor
Christopher Richard Diorio
Eric C Ehrnsperger
Jonathan Marc Cohen
Kadum A Al Shareffi
Syed M Shah
Xu Meng
Original Assignee
Wyeth Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44148539&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112012022873(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Llc filed Critical Wyeth Llc
Publication of BR112012022873A2 publication Critical patent/BR112012022873A2/pt
Publication of BR112012022873B1 publication Critical patent/BR112012022873B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/06—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with a hetero atom directly attached in position 14
    • C07D489/08—Oxygen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Inorganic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

formulações orais e sais lipofílicos de metilnaltrexona. a presente invenção refere-se a composições que compreendem metilnaltrexona ou um sal da mesma, e composições e formulações da mesma, para administração oral.
BR112012022873-0A 2010-03-11 2011-03-10 Composição farmacêutica para administração oral compreendendo brometo de metilnaltrexona e dodecil sulfato de sódio BR112012022873B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US31301810P 2010-03-11 2010-03-11
US61/313,018 2010-03-11
PCT/US2011/027913 WO2011112816A1 (en) 2010-03-11 2011-03-10 Oral formulations and lipophilic salts of methylnaltrexone

Publications (2)

Publication Number Publication Date
BR112012022873A2 true BR112012022873A2 (pt) 2016-08-30
BR112012022873B1 BR112012022873B1 (pt) 2021-09-14

Family

ID=44148539

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012022873-0A BR112012022873B1 (pt) 2010-03-11 2011-03-10 Composição farmacêutica para administração oral compreendendo brometo de metilnaltrexona e dodecil sulfato de sódio

Country Status (32)

Country Link
US (8) US8524276B2 (pt)
EP (2) EP3178472B1 (pt)
JP (4) JP6143409B2 (pt)
KR (2) KR101913102B1 (pt)
CN (2) CN107308125B (pt)
AR (1) AR080491A1 (pt)
AU (1) AU2011224275B2 (pt)
BR (1) BR112012022873B1 (pt)
CA (1) CA2789798C (pt)
CL (1) CL2012002192A1 (pt)
CO (1) CO6630134A2 (pt)
CR (1) CR20120476A (pt)
EA (1) EA029096B1 (pt)
EC (1) ECSP12012208A (pt)
ES (1) ES2623926T3 (pt)
GE (1) GEP201606550B (pt)
GT (1) GT201200247A (pt)
HK (1) HK1245673A1 (pt)
HU (1) HUE033133T2 (pt)
IL (1) IL221452A (pt)
MA (1) MA34146B1 (pt)
MX (2) MX368805B (pt)
MY (1) MY160727A (pt)
NZ (3) NZ601595A (pt)
PE (1) PE20130063A1 (pt)
PL (2) PL3178472T3 (pt)
SG (3) SG10201501821RA (pt)
TN (1) TN2012000392A1 (pt)
TW (2) TWI605814B (pt)
UA (2) UA123856C2 (pt)
WO (1) WO2011112816A1 (pt)
ZA (1) ZA201808498B (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2368553T1 (sl) 2003-04-08 2015-05-29 Progenics Pharmaceuticals, Inc. Farmacevtske formulacije, vsebujoče metilnatrekson
MX2009010550A (es) 2007-03-29 2009-12-14 Progenics Pharm Inc Formas de cristal de bromuro de (r)-n-metilnaltrexona y uso de las mismas.
WO2008153725A2 (en) 2007-05-25 2008-12-18 North Carolina State University Viral nanoparticle cell-targeted delivery platform
NZ601595A (en) 2010-03-11 2015-01-30 Wyeth Llc Oral formulations and lipophilic salts of methylnaltrexone
US8627816B2 (en) 2011-02-28 2014-01-14 Intelliject, Inc. Medicament delivery device for administration of opioid antagonists including formulations for naloxone
US8939943B2 (en) 2011-01-26 2015-01-27 Kaleo, Inc. Medicament delivery device for administration of opioid antagonists including formulations for naloxone
JP2015501849A (ja) * 2011-12-19 2015-01-19 サリックス ファーマスーティカルズ，リミテッド メチルナルトレキソンの経口組成物を用いたオピオイド誘導性便秘症の治療及び予防のための方法
WO2015191686A1 (en) * 2014-06-10 2015-12-17 Salix Pharmaceuticals, Inc. Methods of administering methylnaltrexone
US10722510B2 (en) * 2014-07-08 2020-07-28 Hikma Pharmaceuticals Usa Inc. Liquid naloxone spray
US11135155B2 (en) 2014-07-08 2021-10-05 Hikma Pharmaceuticals Usa Inc. Liquid naloxone spray
US10441538B2 (en) * 2014-07-08 2019-10-15 Hikma Pharmaceuticals Usa Inc. Liquid naloxone spray
US10617686B2 (en) * 2014-07-08 2020-04-14 Hikma Pharmaceuticals Usa Inc. Liquid naloxone spray
US9642848B2 (en) * 2014-07-08 2017-05-09 Insys Development Company, Inc. Sublingual naloxone spray
CA3002137A1 (en) 2014-10-17 2016-04-21 Salix Pharmaceuticals, Inc. Use of methylnaltrexone to attenuate tumor progression
WO2020225395A1 (en) 2019-05-07 2020-11-12 Bausch Health Ireland Limited Liquid oral dosage formulations of methylnaltrexone
CA3142214A1 (en) 2019-06-03 2020-12-10 Bausch Health Ireland Limited Use of methylnaltrexone and rifaximin for treatment of increased gut permeability or associated disorders
EP4142727A1 (en) 2020-05-02 2023-03-08 Bausch Health Ireland Limited Methods of reducing mortality risk in subjects suffering from an underlying disease or condition by administration of methylnaltrexone
WO2023031955A1 (en) * 2021-08-28 2023-03-09 Redasani Vijayendrakumar Virendrakumar Ji Oral pharmaceutical compositions of methylnaltrexone and salt thereof

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4176186A (en) 1978-07-28 1979-11-27 Boehringer Ingelheim Gmbh Quaternary derivatives of noroxymorphone which relieve intestinal immobility
US4861781A (en) 1986-03-07 1989-08-29 The University Of Chicago Quaternary derivatives of noroxymorphone which relieve nausea and emesis
US4719215A (en) 1986-03-07 1988-01-12 University Of Chicago Quaternary derivatives of noroxymorphone which relieve nausea and emesis
CA1297218C (en) 1986-03-14 1992-03-10 Edward David Weil Thermally stable diphosphonate-type flame retardant additive for plastics
US5102887A (en) 1989-02-17 1992-04-07 Arch Development Corporation Method for reducing emesis and nausea induced by the administration of an emesis causing agent
US5780012A (en) 1990-06-21 1998-07-14 Huland; Edith Method for reducing lung afflictions by inhalation of cytokine solutions
AU5171293A (en) 1992-10-14 1994-05-09 Regents Of The University Of Colorado, The Ion-pairing of drugs for improved efficacy and delivery
US5866154A (en) 1994-10-07 1999-02-02 The Dupont Merck Pharmaceutical Company Stabilized naloxone formulations
DE19651551C2 (de) 1996-12-11 2000-02-03 Klinge Co Chem Pharm Fab Opioidantagonisthaltige galenische Formulierung
SK282549B6 (sk) 1997-02-14 2002-10-08 G�decke Aktiengesellschaft Spôsob stabilizácie naloxonhydrochloridu
US6559158B1 (en) 1997-11-03 2003-05-06 Ur Labs, Inc. Use of methylnaltrexone and related compounds to treat chronic opioid use side affects
US20030158220A1 (en) 1997-11-03 2003-08-21 Foss Joseph F. Use of methylnaltrexone and related compounds to treat chronic opioid use side effects
US5972954A (en) 1997-11-03 1999-10-26 Arch Development Corporation Use of methylnaltrexone and related compounds
US6274591B1 (en) 1997-11-03 2001-08-14 Joseph F. Foss Use of methylnaltrexone and related compounds
ATE210983T1 (de) 1997-11-03 2002-01-15 Stada Arzneimittel Ag Stabilisiertes kombinationsarzneimittel enthaltend naloxone und ein opiatanalgetikum
GB0100115D0 (en) 2001-01-04 2001-02-14 Alchemia Pty Ltd Delivery systems
DE60238756D1 (de) * 2001-05-11 2011-02-10 Endo Pharmaceuticals Inc Opioid enthaltende arzneiform gegen missbrauch
EP1404323B1 (en) 2001-06-05 2009-10-28 The University of Chicago Use of methylnaltrexone to treat immune suppression
LT1436012T (lt) 2001-10-18 2018-04-10 Nektar Therapeutics Opioidų antagonistų polimerų konjugatai
CA2468525A1 (en) 2001-11-29 2003-06-12 Schering Corporation Process for the preparation of compositions having an increased amount of pharmaceutically active salts of rotamers of 4-[4-[(1r)-[4-(trifluoromethyl)phenyl]-2-methoxyethyl]-(3s)-methyl-1-piperazinyl]-4-methyl-1-[(4,6-dimethyl-5-pyrimidinyl)carbonyl]
MXPA04008772A (es) 2002-03-14 2004-12-06 Euro Celtique Sa Composiciones de clorhidrato de naltrexona.
US20030191147A1 (en) 2002-04-09 2003-10-09 Barry Sherman Opioid antagonist compositions and dosage forms
RU2373936C2 (ru) 2003-04-08 2009-11-27 Проджиникс Фармасьютикалз, Инк. Применение метилналтрексона для лечения синдрома раздраженного кишечника
JP2006522819A (ja) * 2003-04-08 2006-10-05 プロジェニックス ファーマシューティカルズ，インコーポレーテッド 緩下薬および末梢オピオイドアンタゴニストを組み合わせた便秘の組み合わせ療法
SI2368553T1 (sl) 2003-04-08 2015-05-29 Progenics Pharmaceuticals, Inc. Farmacevtske formulacije, vsebujoče metilnatrekson
CN1852687B (zh) * 2003-07-15 2014-01-22 赢创有限公司 控释组合物的制备方法
US8946262B2 (en) 2003-12-04 2015-02-03 Adolor Corporation Methods of preventing and treating gastrointestinal dysfunction
CN100528162C (zh) 2003-12-19 2009-08-19 先灵公司 药物组合物
DE602004031767D1 (de) * 2003-12-31 2011-04-21 Bend Res Inc Stabilisierte pharmazeutische feste zusammensetzungen von arzneimitteln mit geringer löslichkeit, poloxameren und stabilisierenden polymeren
CN1294728C (zh) 2004-08-05 2007-01-10 华为技术有限公司 边缘路由器提供服务质量保证的方法及系统
WO2006039705A2 (en) 2004-09-30 2006-04-13 Becton, Dickinson And Company Method for reducing or eliminating residue in a glass medical container and container made in accordance therewith
US20060177380A1 (en) * 2004-11-24 2006-08-10 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of orally administered pharmaceutical products
AR057035A1 (es) * 2005-05-25 2007-11-14 Progenics Pharm Inc SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
TWI489984B (zh) * 2006-08-04 2015-07-01 Wyeth Corp 用於非經腸道傳輸化合物之配方及其用途
WO2008021394A2 (en) * 2006-08-15 2008-02-21 Theraquest Biosciences, Llc Pharmaceutical formulations of cannabinoids and method of use
US8091568B2 (en) * 2006-08-16 2012-01-10 Novartis Ag Temporal photo-bleaching of colored lens care solutions and use thereof
US20080233156A1 (en) * 2006-10-11 2008-09-25 Alpharma, Inc. Pharmaceutical compositions
TW200843802A (en) 2007-02-09 2008-11-16 Drugtech Corp Compositions for improving gastrointestinal nutrient and drug absorption
MX2009010550A (es) * 2007-03-29 2009-12-14 Progenics Pharm Inc Formas de cristal de bromuro de (r)-n-metilnaltrexona y uso de las mismas.
PT2139890E (pt) * 2007-03-29 2014-09-03 Wyeth Llc Antagonistas do receptor opióide periférico e respectivas utilizações
JP5178064B2 (ja) * 2007-06-27 2013-04-10 富士フイルム株式会社 金属表面粗化層を有する金属層積層体及びその製造方法
EP2300009A1 (en) * 2008-05-07 2011-03-30 Nektar Therapeutics Oral administration of peripherally-acting opioid antagonists
CA2676881C (en) 2008-09-30 2017-04-25 Wyeth Peripheral opioid receptor antagonists and uses thereof
JP5525247B2 (ja) * 2009-08-04 2014-06-18 株式会社神戸製鋼所 高強度で曲げ加工性に優れた銅合金
NZ601595A (en) 2010-03-11 2015-01-30 Wyeth Llc Oral formulations and lipophilic salts of methylnaltrexone
TW201235609A (en) * 2010-07-13 2012-09-01 Koninkl Philips Electronics Nv Low cost mounting of LEDs in TL-retrofit tubes

Also Published As

Publication number Publication date
US9314461B2 (en) 2016-04-19
TW201622724A (zh) 2016-07-01
US20140249171A1 (en) 2014-09-04
JP2016029054A (ja) 2016-03-03
US10307417B2 (en) 2019-06-04
NZ703564A (en) 2016-08-26
ECSP12012208A (es) 2015-03-31
SG10201606618PA (en) 2016-09-29
EA201270741A1 (ru) 2013-02-28
CL2012002192A1 (es) 2012-09-28
CN107308125A (zh) 2017-11-03
MA34146B1 (fr) 2013-04-03
AU2011224275A1 (en) 2012-08-23
KR20130010900A (ko) 2013-01-29
AR080491A1 (es) 2012-04-11
JP2011190259A (ja) 2011-09-29
CA2789798C (en) 2020-09-22
US20190117645A1 (en) 2019-04-25
IL221452A (en) 2017-07-31
KR101982482B1 (ko) 2019-05-27
US8956651B2 (en) 2015-02-17
US20120070495A1 (en) 2012-03-22
IL221452A0 (en) 2012-10-31
JP6429955B2 (ja) 2018-11-28
TN2012000392A1 (en) 2014-01-30
KR20180118260A (ko) 2018-10-30
PL3178472T3 (pl) 2022-02-14
MX2012009125A (es) 2012-09-07
PE20130063A1 (es) 2013-02-11
EP2371357A1 (en) 2011-10-05
MX349145B (es) 2017-07-14
JP2017206553A (ja) 2017-11-24
US20200121673A1 (en) 2020-04-23
GT201200247A (es) 2013-09-11
CO6630134A2 (es) 2013-03-01
SG183133A1 (en) 2012-09-27
EP3178472A1 (en) 2017-06-14
MY160727A (en) 2017-03-15
JP6647368B2 (ja) 2020-02-14
CR20120476A (es) 2012-11-30
US20130330407A1 (en) 2013-12-12
JP2019034958A (ja) 2019-03-07
EA029096B1 (ru) 2018-02-28
US20190314365A1 (en) 2019-10-17
NZ702826A (en) 2016-08-26
TWI605814B (zh) 2017-11-21
HK1245673A1 (zh) 2018-08-31
ZA201808498B (en) 2019-08-28
MX368805B (es) 2019-10-17
US20160206612A1 (en) 2016-07-21
CN102918039B (zh) 2017-06-09
HUE033133T2 (en) 2017-11-28
GEP201606550B (en) 2016-10-10
EP2371357B1 (en) 2017-02-01
ES2623926T3 (es) 2017-07-12
KR101913102B1 (ko) 2018-10-31
EP3178472B1 (en) 2021-10-27
US20190117646A1 (en) 2019-04-25
PL2371357T3 (pl) 2017-09-29
US10376505B2 (en) 2019-08-13
TW201141479A (en) 2011-12-01
BR112012022873B1 (pt) 2021-09-14
NZ601595A (en) 2015-01-30
WO2011112816A1 (en) 2011-09-15
US10507206B2 (en) 2019-12-17
SG10201501821RA (en) 2015-05-28
UA111717C2 (uk) 2016-06-10
CN102918039A (zh) 2013-02-06
US8524276B2 (en) 2013-09-03
CN107308125B (zh) 2021-07-16
AU2011224275B2 (en) 2015-10-01
CA2789798A1 (en) 2011-09-15
JP6143409B2 (ja) 2017-06-07
UA123856C2 (uk) 2021-06-16
TWI589293B (zh) 2017-07-01

Similar Documents

Publication Publication Date Title
BR112012022873A2 (pt) formulações orais e sais lipofílicos de metilnaltrexona
CY1125100T1 (el) Υδατικο φαρμακευτικο σκευασμα ταπενταδολης για απο του στοματος χορηγηση
CY1122786T1 (el) Δοσολογικα σχηματα για ενωσεις κατηγοριας εχινοκανδινης
CY1118379T1 (el) Αναστολεις ιου ηπατιτιδας c
BR112014019171A8 (pt) Composições intranasais de dexdetomida e seus métodos de uso
CO7091182A2 (es) Inhibidores de beta-lactamasa isoxazol
BR112015003376A2 (pt) composto ou sal farmaceuticamente aceitável do mesmo , composição farmacêutica e usos de quantidade eficiente
BRPI0916922A2 (pt) composição farmacêutica de liberação prolongada de entacapona ou sais da mesma
BR112013007362A2 (pt) composição farmacêutica
BR112014001600A2 (pt) composto inibidor do trajeto de sinalização notch
BR112013017169A2 (pt) composições farmacêuticas de ferro para administração oral
BR112013019522A2 (pt) dissialil lacto-n-tetraose (dslnt) ou as variantes, os isômeros, os análogos e os derivados da mesma para prevenir ou inibir doença do intestino
BR112015011430A2 (pt) composição para liberação imediata e prolongada
ECSP12012290A (es) Formulaciones farmacéuticas
BR112013004016A2 (pt) formulações á base de nalbufina e as respectivas utilizações
BR112012019997A2 (pt) composições de cuidado oral
CY1115556T1 (el) Φαρμακευτικη συνθεση για χορηγηση απο το στομα η οποια περιλαμβανει ετεξιλικη δαβιγατρανη
MX347105B (es) Composiciones farmaceuticas que comprenden hidromorfona y naloxona.
MX340983B (es) Composiciones farmaceuticas y nutraceuticas de acido abscisico.
EA033171B1 (ru) Полутвёрдая фармацевтическая композиция на водной основе, содержащая тапентадол
BR112014008668A2 (pt) moduladores de receptor de andrógeno seletivo
BR112013016615A2 (pt) uso de dronedarona para a preparação de um medicamento para uso no controle do risco de lesão hepática
BR112015005285B8 (pt) Composições enxaguantes bucais para o tratamento da sensibilidade dentária
UY34080A (es) Composición farmacéutica para administración oral que comprende fexofenadina y métodos de preparación
BR112015004115A2 (pt) composições farmacêuticas compreendendo flurbiprofeno

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: A CLASSIFICACAO ANTERIOR ERA: C07D 471/00

Ipc: C07D 471/00 (2006.01), A61K 31/385 (2006.01), A61P

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 10/03/2011, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.